CD274 and breast cancer: However, resistance to PD-L1 checkpoint therapy has been reported in BC patients despite the high expression of PD-L1 on CTCs [161], suggesting that CTCs may possess compensatory immune-escape mechanisms beyond PD-L1 expression that promotes their survival.